Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB 11285 +/- atezolizumab in advanced solid tumors
NCT04096638Phase 1Completed
- Sponsor
- invoX Pharma
- Start
- Sep 2019
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SB 11285 in solid tumor (advanced stage), melanoma and head and neck squamous cell carcinoma (HNSCC) (5 arms), sponsored by invoX Pharma. Primary endpoints: Dose-Limiting Toxicity, Maximum Tolerated Dose and 3 more. Started Sep 2019; status: completed.
02
Drugs
SB 11285
03
Conditions
solid tumor (advanced stage)melanomahead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04096638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04096638.